CD52 Is Elevated on B cells of SLE Patients and Regulates B Cell Function

Area of Science:

• Immunology
• Autoimmunity
• Cell Biology

Background:

• Systemic lupus erythematosus (SLE) involves B cell dysregulation and autoantibody production.
• B cell hyperactivity is a hallmark of SLE pathogenesis.
• The precise regulatory mechanisms of B cell activation in SLE are not fully understood.

Purpose of the Study:

• To investigate the role of CD52 in B cell regulation in Systemic Lupus Erythematosus (SLE).
• To explore the functional consequences of altered CD52 expression in SLE pathogenesis.
• To elucidate the mechanism by which CD52 modulates B cell receptor (BCR) signaling.

Main Methods:

• Single-cell RNA sequencing of B cells from healthy donors and SLE patients.
• Flow cytometry to quantify B cell surface CD52 and plasma soluble CD52.
• Functional assays using CD52-deficient cell lines and recombinant CD52-Fc.
• Analysis of B cell signaling pathways, including BCR activation and CD52 cleavage.

Main Results:

• SLE patients exhibit significantly upregulated CD52 expression on B cells and in plasma, correlating with disease activity.
• CD52-deficient B cells show hyperresponsiveness to BCR signaling, indicating an inhibitory role for surface CD52.
• Antigen-specific BCR activation triggers CD52 cleavage, reducing surface levels and inhibiting BCR signaling, partly via Siglec-10.
• Soluble CD52 suppresses B cell function, reduces surface immunoglobulin and CXCR5, and promotes B cell anergy.

Conclusions:

• CD52 functions as a critical homeostatic regulator of B cell responses by inhibiting BCR signaling.
• Cleavage of CD52 upon antigen engagement releases soluble forms that suppress B cell activity in autocrine and paracrine manners.
• Elevated CD52 expression in SLE may represent a compensatory mechanism to control B cell hyperactivity and maintain self-tolerance.